KRAS G13D
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma (NCT07083479) | Elicio Therapeutics |
Track KRAS G13D automatically
Every clearance here is in the API, with alerts when new ones post.